Analysts’ Recent Ratings Changes for Editas Medicine (EDIT)

Several analysts have recently updated their ratings and price targets for Editas Medicine (NASDAQ: EDIT):

• 3/10/2026 – Editas Medicine was upgraded by JonesTrading from “hold” to “buy”. They now have a $8.00 price target on the stock.
• 3/9/2026 – Editas Medicine was given a new $6.00 price target by Robert W. Baird.
• 3/9/2026 – Editas Medicine had its “buy” rating reaffirmed by TD Cowen.
• 3/9/2026 – Editas Medicine had its “buy” rating reaffirmed by Chardan Capital. They now have a $3.50 price target on the stock.
• 1/21/2026 – Editas Medicine had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.